Lane 1: IgG; Lane 2: T-cell receptor α and Lane 3: NFκB-1 Lane 4: Cyclin D1; Lane 5: P21; Lane 6: c-fos Lane 7: P0; Lane 8: P1 and Lane 9: EGFR

Figure 2:Effects of treatments of cultured OC-3-VGH ovarian cancer cells with goat anti-human IgG (GαHIgG) ( ), rabbit anti-T cell receptors β (RαTCRβ) ( ), mRP215 ( ), anti-TLR-4 (αTLR4) ( ) and LPS (), respectively on the expressions of genes involved in cell proliferation, protein synthesis, cell cycle regulations as well as the innate immunity; Expressions of 9 genes involved were adjusted with that of GAPDH. The negative control ( ) with normal mouse IgG (NMIgG) was considered 100% in all cases. Antibody concentration of 10 μg/ml was used for all parallel studies of comparisons. List of genes involved: Changes in selected gene regulations upon treatments of cultured C-33A cervical cancer cells for comparison with those of ovarian cancer cells demonstrated in (A), (B) and (C), respectively. Lane 1: IgG; Lane 2: TCR; Lane 3: NFκB-1; and Lane 7: P1. In the case of C-33A cervical cancer cells, the expression of EGFR gene is too low to be quantitated. Effects of anti-TLR-4 and LPS on the gene regulation of IgG are presented in (A) and (D), respectively for OC-3-VGH and C-33A cancer cells. All data presented are statistically significant at P<0.01 except those labeled with * which are not statistical different from the negative control.